Abstract Allogeneic hematopoietic cell transplantation (HCT) is a potential cure for patients with peripheral T-/NK-cell lymphomas (PTCL), but its application is understudied. This prospective trial evaluates a unique reduced-intensity (RIC) transplantation platform in 31 patients with PTCL (NCT03922724). One-year progression-free survival, the primary endpoint, is 53% (95% CI 29-72%) on the RIC arm and 60% (95% CI 25-83%) on the modified-RIC arm. The 3-year overall survival is 61% (95% CI 42-76%), with relapse estimated at 18% (95% CI 6-34%) at 3 years. Transplant-related mortality was 24% (95% CI 10-41%) at 1-year, low at 11% (95% CI 2-29%) for patients ≤60 years but 56% (95% CI 17-82%) for patients >60 years, p = 0.01. There was no grade III-IV acute graft-versus-host disease, while chronic graft-versus-host disease was estimated at 23% (95 CI 10-38%) at 2 years. This study demonstrates a benefit regardless of pre-transplantation disease status, challenging the requirement of remission for HCT.
Rechache et al. (Thu,) studied this question.